Brief: Revance Therapeutics Q3 EPS USD -1.63
08/11/2023 21:06
Nov 08 (Reuters) - Revance Therapeutics Q3 product revenue USD 54.109 million. * Q3 net income USD -141.176 million * Q3 operating expenses USD 196.069 million * Q3 pretax profit USD -140.876 million * Q3 operating income USD -139.293 million
Recent news on Revance Therapeutics
See all newsBrief: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup